Tuesday, March 21, 2023

The 7th China Yiwu International Hardware & Electrical Appliances Fair to Showcase Best of Hardware and Electrical Products

 A one-stop hardware & electrical appliances sourcing platform for both domestic and global buyers

(BUSINESS WIRE) -- As the sole professional exhibition platform for hardware and electrical products in Yiwu City of China, the 7th China Yiwu International Hardware & Electrical Appliances Fair will be held at Yiwu International Expo Center on April 20-22, 2023.

This year, the total exhibition area will measure 50,000 square meters, which is 10,000 square meters larger than that of last year. Expected to gather over 1,400 companies and 60,000 professional buyers, the event will provide a comprehensive platform for hardware and electrical buyers from home and abroad to find the best hardware and electrical products.

At the Fair, hardware and electrical products will be showcased in four major categories: hardware tools, building hardware, electronics and electrical appliances, and labor protection products.

Hardware tools: hand tools, electric tools, air tools, general accessories, automotive and motorcycle tools, garden tools, measuring tools, cutting tools, casters, and more.

Building hardware: plumbing equipment, bathroom fixtures, building materials, decorative hardware, door and window accessories, valves, standard fasteners, bearings, chains, springs, locks, fire equipment, anti-theft equipment, and more.

Electronics and electrical appliances: lighting fixtures and decorations, electrical products, electrical materials, instruments and meters, plugs and sockets, electric razors, clocks, home appliances, smart lighting controllers, VR glasses, wearable electronic gear, portable power banks, digital products, virtual platforms, and more.

Labor protection supplies: safety helmets, respiratory protective gear, eye (face) protection gear, ear protection gear, protective shoes, gloves, protective clothing, fall protection gear, dust hats, general work clothes, general labor protective leather shoes, foot covers, waterproof boots, raincoats, knee pads, and more.

Find out more information about the 7th China Yiwu Hardware and Electrical Appliances Fair and register for your passes to the fair today!

Official website:


Pre-registration: http://buyer.yiwufair.com/dreg/#/login?lang=en&origin=1253&fquestionId=270


View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005329/en/




Cici Hu



Campbell Lutyens and J.P. Morgan announce strategic collaboration in the secondary advisory market

 (BUSINESS WIRE) -- Campbell Lutyens and J.P. Morgan are pleased to announce the establishment of a strategic collaboration to jointly offer their advisory services on single-asset and concentrated multi-asset continuation fund secondary transactions. The offering will enable clients to benefit from Campbell Lutyens’ and J.P. Morgan’s global, market leading secondary and Investment banking advisory practices, respectively.

The proposition combines J.P. Morgan’s global top-tier investment banking services with Campbell Lutyens’ leading global placement and secondary advisory platform, creating a best-in-class global offering for single-asset and concentrated multi-asset continuation funds. It will be available for clients across all regions and sectors in which Campbell Lutyens and J.P. Morgan both operate. The offering provides access to Campbell Lutyens’ secondaries expertise focused on fund structuring and capital raising from secondaries and institutional investors along with J.P. Morgan’s M&A services, industry expertise and capital raising capabilities.

“We are delighted to be working with J.P. Morgan and believe that our combined capabilities and experience offer a compelling proposition in the secondary advisor market,” said Immanuel Rubin, head of European and Asia Pacific secondary advisory and Gerald Cooper, head of North American secondary advisory at Campbell Lutyens. “Our clients will now have the option to benefit from the resources and expertise of both of our franchises when seeking to complete these types of complex secondary transactions.”

“The secondaries market is a fast growing and important market for our private equity and infrastructure clients globally,” said Anu Aiyengar, Global Head of Mergers & Acquisitions at J.P. Morgan. “Through our unique collaboration and complementary skillsets, we will be able to provide our clients with a comprehensive and differentiated service offering for their continuation fund projects.”

Campbell Lutyens has advised on more than US$125 billion of secondary transaction volume, completing over 290 successful secondary portfolio sales and advisory mandates. Its secondary advisory practice includes more than 50 professionals across North America, Europe and Asia Pacific.

About Campbell Lutyens

Campbell Lutyens is a global and independent private markets advisor, providing fund placement, secondary advisory and GP capital advisory services to leading fund managers and investors. With specialist knowledge in private equity, infrastructure, private credit and sustainable investing, the firm has a team of 220 operating from offices in London, Paris, New York, Los Angeles, Chicago, Charlotte, Hong Kong and Singapore.


About J.P. Morgan

J.P. Morgan’s Corporate & Investment Bank is a global leader across banking, markets and securities services. The world’s most important corporations, governments and institutions entrust us with their business in more than 100 countries. With $28.6 trillion of assets under custody and $649.7 billion in deposits, the Corporate & Investment Bank provides strategic advice, raises capital, manages risk and extends liquidity in markets around the world. Further information about J.P. Morgan is available at www.jpmorgan.com.


View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005614/en/




For further information, please contact:

Campbell Lutyens:

Aarti Iyer

Head of Communications

Tel: +1 647 619 1076

E-mail: aiyer@campbell-lutyens.com

J.P. Morgan:

Patrick Burton

Head of Marketing & Communications, EMEA

Tel: +44 20 7134 9041

E-mail: patrick.o.burton@jpmorgan.com

Verisign Reports Internet Has 350.4 Million Domain Name Registrations at the End of the Fourth Quarter of 2022

 (BUSINESS WIRE) -- VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the fourth quarter of 2022 closed with 350.4 million domain name registrations across all top-level domains (TLDs), an increase of 0.5 million domain name registrations, or 0.1%, compared to the third quarter of 2022.1,2 Domain name registrations have increased by 8.7 million, or 2.6%, year over year.1,2

The .com and .net TLDs had a combined total of 173.8 million domain name registrations in the domain name base3 at the end of the fourth quarter of 2022, a decrease of 0.4 million domain name registrations, or 0.2%, compared to the third quarter of 2022. The .com and .net TLDs had a combined increase of 0.3 million domain name registrations, or 0.2%, year over year. As of Dec. 31, 2022, the .com domain name base totaled 160.5 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations.

New .com and .net domain name registrations totaled 9.7 million at the end of the fourth quarter of 2022, compared to 10.6 million domain name registrations at the end of the fourth quarter of 2021.

Total country-code TLD (ccTLD) domain name registrations were 133.1 million at the end of the fourth quarter of 2022, an increase of 0.7 million domain name registrations, or 0.5%, compared to the third quarter of 2022.1,2 ccTLDs increased by 5.7 million domain name registrations, or 4.5%, year over year. The top 10 ccTLDs, as of Dec. 31, 2022, were .cn, .de, .uk, .nl, .ru, .br, .au, .eu, .fr, and .it.1,2

Verisign publishes The Domain Name Industry Brief to provide internet users throughout the world with statistical and analytical research and data on the domain name industry. The Domain Name Industry Brief for the fourth quarter 2022, as well as previous briefs, can be obtained at verisign.com/dnib.

About Verisign

Verisign, a global provider of domain name registry services and internet infrastructure, enables internet navigation for many of the world’s most recognized domain names. Verisign enables the security, stability, and resiliency of key internet infrastructure and services, including providing root zone maintainer services, operating two of the 13 global internet root servers, and providing registration services and authoritative resolution for the .com and .net top-level domains, which support the majority of global e-commerce. To learn more about what it means to be Powered by Verisign, please visit verisign.com.


© 2023 VeriSign, Inc. All rights reserved. VERISIGN, the VERISIGN logo, and other trademarks, service marks, and designs are registered or unregistered trademarks of VeriSign, Inc. and its subsidiaries in the United States and in foreign countries. All other trademarks are property of their respective owners.

1 All figure(s) exclude domain names in the .tk, .cf, .ga, .gq, and .ml ccTLDs. Quarterly and year-over-year trends have been calculated relative to historical figures that have also been adjusted to exclude these five ccTLDs. For further information, please see the Editor’s Note contained in Vol. 19, Issue 1 of The Domain Name Industry Brief.
2The generic TLD, ngTLD, and ccTLD data cited in the brief: (i) includes ccTLD internationalized domain names, (ii) is an estimate as of the time the brief was developed ad (iii) is subject to change as more complete data is received. Some numbers in the brief may reflect standard rounding.
3 The domain name base is the active zone plus the number of domain names that are registered but not configured for use in the respective TLD zone file plus the number of domain names that are in a client or server hold status. The .com and .net domain name registration figures are as reported in Verisign’s most recent SEC filings.


View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005753/en/



Investor Relations: David Atchley, datchley@verisign.com, + 1 703-948-3447
Media Relations: Dave McGuire, davmcguire@verisign.com, + 1 703-948-3800

"Captain Tsubasa: Dream Team” Debuts New Players Wearing the FC BARCELONA Official Uniform and Monthly Livestream on YouTube


 KLab Inc., a leader in online mobile games, announced that its head-to-head football simulation game Captain Tsubasa: Dream Team will hold the FC BARCELONA Official Campaign from Friday, March 17th. The campaign will feature Tsubasa Ozora, Xavii, and Payol wearing the FC BARCELONA official kit. See the original press release (https://www.klab.com/en/press/) for more information.

In addition, the campaign will include a login bonus, event missions, special event, and the Dreamball Exchange where users will have a chance to get the new kits as well. Be sure to check the in-game notifications for more information on the campaigns.

Ramadan Daily Scenarios

Users can play these limited scenarios once a day during the event period between March 24th to April 21st. Be sure to play for a chance to receive great in-game rewards.

Monthly Livestream on YouTube Live

In-game notifications and the latest information on any new players or updates will be delivered in both Japanese and English for your enjoyment.

Livestream Schedule

Thursday, March 30th from 21:00 JST (UTC+9)

YouTube Channel: https://www.youtube.com/channel/UCTgOPO7kIQ35YzB7SBIQoWQ/

*The broadcast is expected to be in Japanese and English.

*Livestream contents are subject to change without notice.

Overview of Captain Tsubasa: Dream Team

Supported OSes:                                Android™ 4.4+, iOS 11.0+, HarmonyOS 2.0+

Genre:                                                   Head-to-head football simulation game

Price:                                                     Free-to-play (In-app purchases available)

Supported Regions:                          Global (Excludes Japan and Mainland China)

Official Website:                                 https://www.tsubasa-dreamteam.com/en

Official Twitter Account:                  @tsubasaDT_en

Official Facebook Page:                   https://www.facebook.com/tsubasaDTen

Official YouTube Channel:        https://www.youtube.com/channel/UCTgOPO7kIQ35YzB7SBIQoWQ/

Official Discord Channel:                 https://discord.gg/6tyEs48

Copyright:                                    ©Yoichi Takahashi/SHUEISHA

© KLabGames

Download here:

App Store: https://itunes.apple.com/app/id1293738123

Google Play: https://play.google.com/store/apps/details?id=com.klab.captain283.global

AppGallery: https://appgallery.huawei.com/#/app/C105375049

About Klab

KLab is a leader in online mobile gaming. Founded in 2000 and headquartered in Tokyo, the company is listed on the 1st Section of the Tokyo Stock Exchange. KLab has consistently ranked as one of the top 52 grossing game publishers worldwide since 2012. With its emphasis on quality and innovative games, KLab continues to grow at a rapid pace, expanding beyond the Japanese market with an office in Shanghai. For more information about KLab, please visit http://www.klab.com/jp/english/.


Melwyn Abraham  


Monday, March 20, 2023

Cirium Launches the First Airline Routes Tool Based on Satellite-Based Flight Tracking

 In an industry first, the Airline Routes tool analyzes an airline’s routes using satellite-based flight tracking data to identify actual flights flown by aircraft type

Businesses can identify aircraft demand and where airlines are growing or reducing their network to factor development opportunities or risks into decision making

An analysis using the tool shows how Indian low-cost-carrier IndiGo flew 172 flights between Delhi and Kathmandu using Airbus A320s this January compared with no flights in January 2022, and five times the flights with A320s between Dubai and Ahmedabad year-over-year


(BUSINESS WIRE) -- Cirium, the aviation analytics leader, has launched the aviation industry’s first Airline Routes tool to identify actual flights flown by aircraft type.

It uses applied analytics to derive routes flown by airlines based on satellite-based flight tracking and fuses this with advanced fleet data.

The new premium Routes tool is part of Ascend Profiles, a visual descriptive analytics tool which enables businesses to quickly view aircraft intelligence by airline or lessor.

Businesses such as aircraft lessors, banks or aircraft manufacturers are empowered to identify the aircraft flown by route for 1,700 airlines and factor development opportunities or risk into their decision making.

By leveraging satellite-based flight tracking data the tool identifies what routes and aircraft airlines actually flew rather than what they planned to fly providing the most accurate flight completion picture.

Kevin Hightower, Cirium VP of Product said: “The Airline Routes tool is the first of its kind to bring together such advanced data – the satellite-based flight tracking and the comprehensive fleet data – meaning businesses can conduct quick yet accurate due diligence on an airline portfolio.

“Understanding which aircraft an airline is actually flying and on what routes is critical to identify where aircraft demand may be and whether an airline is growing or reducing their network.”

India is one of the markets in the spotlight currently, as air travel is helping to boost economic growth in the region. Low-cost-carrier, IndiGo recently announced it was looking to grow its international network and further solidify its domestic operations.

According to Ascend Profiles, IndiGo has a fleet of 306 aircraft – (273 in service and 33 in storage), plus 501 on order. Of the delivered fleet, 36% are on operating lease.

The Routes tool shows which two-way international routes IndiGo was operating this January which it was not in January 2022. For example, 172 flights were tracked on the newly added route between Indira-Gandhi International Airport in Delhi to Tribhuvan International in Kathmandu. All operated using Airbus A320s.

Additionally, the new tool shows the bi-directional routes for which IndiGo has ramped up operations. The carrier saw the most significant growth on the Singapore – Bengaluru route, where it completed 62 flights, all using A320s, this January versus only one flight, using an A321, last January.

IndiGo also substantially increased its operations this year on the Dubai – Ahmedabad route, completing five times the number of flights in Jan 23 when compared with Jan 22.

The Airline Routes tool is part of Ascend Profiles which visualizes aircraft intelligence of airline or lessor profiles and provides quick and accurate insights showing the latest 12-month year-over-year flights flown by an airline’s routes and can be viewed by flights, seats and ASKs. The tool is available as a web-app on desktop, tablet, and mobile. Find out more.

Notes to editors

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit cirium.com.


View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005187/en/




For media enquiries:

Cirium PR: media@cirium.com

The PC Agency (UK and Europe): cirium@pc.agency

Juliett Alpha Media Relations (Americas): cirium@juliettalpha.com

TrainTracks (Japan): Cirium@traintracks.jp


AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

 ZUG, Switzerland - Monday, 20. March 2023

Extensive updates from broad and innovative portfolio also to be presented

The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2 trial, where nemolizumab monotherapy met all primary and key secondary endpoints and demonstrated significant improvements on itch, skin clearance and sleep disturbance in adult patients with prurigo nodularis

Four additional posters explore the disease burden of prurigo nodularis, a debilitating disease with limited treatment options

Twenty-one posters include updates on dermatologic conditions such as sensitive skin, acne, and rosacea, as well as the latest data from the aesthetics portfolio

The company’s commitment to Diversity and Inclusion in Dermatology has been featured through the sponsorship of activities with the George Washington University School of Medicine and their novel educational Dermatology Atlas


(BUSINESS WIRE) -- Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial evaluating the efficacy, safety, pharmacokinetics and immunogenicity of nemolizumab compared with placebo in adult patients with prurigo nodularis. The results were presented as a late-breaking presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting by Dr. Shawn Kwatra, Associate Professor of Dermatology at the Johns Hopkins University School of Medicine. Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.

The phase III OLYMPIA 2 trial met all primary endpoints, showing nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions compared with placebo in adult patients with moderate to severe prurigo nodularis. Results showed that:

56 percent of nemolizumab-treated patients achieved a response in itch intensity, as defined by an at least 4-point improvement in peak-pruritus numerical rating scale (PP-NRS) score, compared to 21 percent in the placebo group (p<0.0001)

38 percent of nemolizumab-treated patients reached treatment success in skin lesions, as defined by an investigator’s global assessment (IGA) score of 0 or 1, compared to 11 percent in the placebo group (p<0.0001)

Key secondary endpoints showed rapid onset of action and significant improvements in itch and sleep disturbance (p<0.0001) as early as week 4:

Over five times as many patients in the nemolizumab group vs placebo achieved significant and clinically meaningful improvement in itch intensity, as defined by a 4-point improvement in PP-NRS - (41.0% for nemolizumab vs 7.7% for placebo p<0.0001)

Nearly four times as many patients in the nemolizumab group versus placebo achieved significant and clinically meaningful improvement in sleep disturbance as measured by a 4-point improvement in sleep disturbance numerical rating scale (SD-NRS) - (37.2% for nemolizumab vs 9.9% for placebo p<0.0001)

The safety profile was consistent with the phase II trial results

“OLYMPIA 2 is a key piece of the largest phase III clinical development program ever undertaken in prurigo nodularis to date. On behalf of my co-investigators worldwide, I am honored and proud to present the study results to the scientific community in a late-breaking presentation. The results confirm the potential of this every four weeks injectable monoclonal antibody targeting the IL-31 receptor alpha, with rapidly acting effects on itch and sleep disturbance, and subsequent improvement of skin lesions.”




Further commitment to diversity in dermatology announced

Also at the congress, Galderma shared an exciting update on the sponsorship of the Atlas initiative, in a highly anticipated booth session focused on Diversity and Inclusion in Dermatology. The unique educational session explored how to diagnose dermatologic conditions in an array of skin tones, leveraging the renowned book and online gallery ‘Full Spectrum of Dermatology: A Diverse and Inclusive Atlas’, from the George Washington University School of Medicine. The event took place on Friday, March 17 and was hosted by editors of the Atlas, Dr. Adam Friedman and Dr. Misty Eleryan. As part of the Galderma sponsorship, copies of the Atlas book are being distributed throughout the AAD congress. Galderma is also proud to be providing an additional financial grant to pilot a pathway for other healthcare professionals to contribute to the online gallery.

“We are so pleased that we’re able to bring so much powerful new data to this year’s AAD congress. The data premiere from OLYMPIA 2 confirms the potential that nemolizumab is expected to improve outcomes for people with prurigo nodularis, which can have such a profound impact on the lives of those affected. Beyond this, our continued involvement and investment in the Atlas program demonstrates our commitment to address every skin need, with diversity and inclusion at the very heart of that promise.”




Extensive updates from Galderma’s broad and innovative portfolio through posters and presentation sessions

Galderma is the only pure-play dermatology category leader, with more than 40 years of heritage in dermatology. Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD. More details on Galderma’s scientific poster presentations can be found here.

About the OLYMPIA 2 trial

OLYMPIA 2 was a randomized, double-blind, placebo-controlled phase III clinical trial, to assess the efficacy and safety of nemolizumab monotherapy compared with placebo in patients at least 18 years of age with prurigo nodularis after a 16-week treatment period. The trial also assessed pharmacokinetics and immunogenicity of nemolizumab compared to placebo. OLYMPIA 2 included 274 patients with moderate-to-severe prurigo nodularis.

About prurigo nodularis

Prurigo nodularis is a debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense itch.1,2,3 Prurigo nodularis affects an estimated 72 per 100,000 adults aged 18-64 years in the United States, primarily middle-aged women and disproportionately people of African descent.1,4

About nemolizumab

Nemolizumab is an investigational drug and Galderma has not received approval for any indication in any country. Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31. IL-31 is a neuroimmune cytokine that is recognized as driving multiple disease mechanisms in both prurigo nodularis and atopic dermatitis. With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while also directly acting on structural cells in the skin. Nemolizumab was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis, a status reconfirmed in February 2023.

About Galderma

Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane®, Dysport®, Azzalure®, Alluzience® and Sculptra® in Injectable Aesthetics; Soolantra®, Epiduo®, Differin®, Aklief®, Epsolay®, Twyneo®, Oracea®, Metvix®, Benzac® and Loceryl® in Therapeutic Dermatology; and Cetaphil® and Alastin® in Dermo-cosmetics. For more information, visit www.galderma.com.


1 Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080

2 Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747-760. doi:10.1016/j.jaad.2020.07.025

3 Whang KA, Mahadevan V, Bakhshi PR, et al. Prevalence of prurigo nodularis in the United States. J Allergy Clin Immunol Pract. 2020;8(9):3240-3241. doi:10.1016/j.jaip.2020.05.051

4 Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi:10.1016/j.jid.2019.07.697


View source version on businesswire.com: https://www.businesswire.com/news/home/20230318005017/en/




For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer


+41 76 315 26 50

Rachel Mooney

Global Franchise Communications


+41 76 261 64 41

Zach Randles-Friedman

Head of U.S. Communications


+1 305 299 5700


Guardforce Security Adopts Hytera Push-to-talk to Improve Operational Efficiency

 (BUSINESS WIRE) -- Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, has been providing Guardforce Security Thailand with its newest Push-to-Talk over Cellular (PoC) radios and Hytera HyTalk software suite to facilitate nationwide instant group communications and better team collaboration among Guardforce staff.

Guardforce Thailand is a major security company that supplies technology-driven security solutions to a wide range of clients across Thailand, including banks, government organizations, retailers, shopping malls, hotels, airports, and enterprises. It currently employs approximately 5,000 security personnel nationwide across its three divisions.

The security provider used to rely on analog two-way radios for communications and found that the limitations of the legacy radio system had a detrimental effect on the efficiency of day-to-day operations. Guardforce, therefore, decided to upgrade to a new communications system with more extensive coverage, greater capacity, and better audio quality.

Guardforce chose Hytera’s PoC solution after extensive research. The one-stop solution, comprising Hytera’s HyTalk platform and PNC380 and PNC360S PoC radios, provides substantial improvements in both connectivity and functionality and serves as the choice of Guardforce moving forward in a competitive security market.

“Our staff is now equipped with Hytera PNC380 and PNC360S PoC radios that allow us to communicate over long distances,” said Kanayos Manaakkarakul, Sale and Innovation Manager of Guardforce. “I would say, these PoC radios have solved many problems for us. They helped our security personnel meet customer requirements with much higher efficiency.”

The partnership between Guardforce and Hytera will lead to more innovations for Guardforce to better serve its clients.

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video, and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission-critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/industries/security.html


Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/53362444/en




Jia Liu

Hytera Communications Corporation Limited


Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis


OSAKA, Japan & CAMBRIDGE, Mass. - Monday, 20. March 2023

  • Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1
  • At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearance of Skin Lesions1
  • Takeda to Start Phase 3 Plaque Psoriasis Study and Expects Topline Results for a Phase 2b Study in Psoriatic Arthritis in FY2023
  • Takeda Will Evaluate TAK-279 in Additional Immune-Mediated Diseases Including Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD), and Explore Further Indications in the Future

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and 30mg dosing arms compared to placebo at 12 weeks.1 These data were presented during a late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting being held March 17-21, 2023 in New Orleans.

“The Phase 2b TAK-279 results demonstrate a strong overall clinical benefit and, importantly, a significant number of patients reached PASI 90 or 100, achieving near-total or total skin clearance,” said April Armstrong, M.D., MPH, clinical investigator in the Phase 2b study and Associate Dean and Professor of Dermatology at the University of Southern California. “These results further support the potential of highly selective TYK2 inhibition to provide an effective and convenient oral treatment option for people living with moderate-to-severe plaque psoriasis who are not achieving optimal skin clearance with current therapies. I look forward to the results of future clinical trials."

In the Phase 2b study, 259 patients were randomized (1:1:1:1:1 ratio) to receive one of four doses of TAK-279 once-daily, or placebo for 12 weeks.1 Results showed:

  • A significantly greater proportion of TAK-279 patients achieved PASI 75 (44%, 68%, 67%; 5mg, 15mg, 30mg, respectively) versus placebo (6%; p<0.001), meeting the study’s primary endpoint.1

  • A significantly greater proportion of TAK-279 patients achieved PASI 90 (21%, 45%, 46%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p<0.001), and PASI 100 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p<0.001 at 30mg).1

  • A significantly greater proportion of TAK-279 patients achieved Physician Global Assessment (PGA) scores of 0/1 (27%, 49%, 52%; 5mg, 15mg, 30mg, respectively) or 0 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (4% [p≤0.001] and 0% [p<0.001 at 30mg], respectively) at 12 weeks.1 A PGA score of 1 indicates almost clear skin and 0 indicates totally clear skin.2

  • There were no statistically significant differences in PASI or PGA response rates seen in the TAK-279 2mg arm* (18%, 2%, 10%, 2%; PASI 75, PASI 100, PGA 0/1, PGA 0, respectively) compared to placebo.1

The frequency of adverse events (AEs) was 53-62% in the treatment arms and 44% in the placebo arm. Most events were mild to moderate in severity. Two serious AEs occurred in one patient (15mg) and were considered unrelated. Changes in laboratory parameters were consistent with known effects of allosteric TYK2 inhibition.1

“These compelling TAK-279 data strengthen its potential for people with moderate-to-severe plaque psoriasis. The highly selective TYK2 inhibition seen with TAK-279 spares inhibition of other members of the Janus kinase (JAK) family, which we believe should avoid JAK-related toxicities,” said Andy Plump, President R&D, Takeda. “We are confident that we can execute a comprehensive development program and deliver a potential best-in-class therapy for patients, given Takeda’s strong background in immune-mediated diseases, including inflammatory bowel disease.”

Based on these Phase 2b results, Takeda will initiate a Phase 3 study of TAK-279 in psoriasis in FY2023. Takeda expects topline results from a Phase 2b study in psoriatic arthritis in FY2023 and will be evaluating TAK-279 in additional immune-mediated diseases including systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD). Other indications will be explored in the future.

Takeda will be hosting a virtual meeting for investors and analysts to discuss these data at 7:00 p.m. EDT on Saturday, March 18 / 8:00 a.m. JST on Sunday, March 19. Please click here to participate.

Results from the Phase 2b study have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2023 (Fiscal Year 2022).

*In the TAK-279 2mg arm, the PASI 90 response rate was 8% with a nominal p-value = 0.037 compared to placebo.1

About Plaque Psoriasis
Psoriasis is a chronic autoimmune disease in which the body’s immune system causes skin cells to multiply too quickly.3 Plaque psoriasis is a common form of psoriasis and is characterized by raised, red patches of skin that are covered by silvery-white scales which can be itchy and painful.3,4 Plaque psoriasis most often appears on the scalp, elbows, knees and lower back, but can appear anywhere on the body.3-5 Globally, an estimated 125 million people are living with psoriasis and about 80-90% of those have plaque psoriasis.5,6

About TAK-279
TAK-279 is a late-stage, highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases.1,7 In preclinical studies, TAK-279 has demonstrated excellent functional selectivity and wide therapeutic margins.8 In Phase 1 studies, TAK-279 showed a good tolerability profile, a dose-dependent trend in exploratory clinical activity and a pharmacokinetic profile allowing for once-daily solid oral dosing.9 TAK-279 is in an ongoing Phase 2b trial in active psoriatic arthritis (NCT05153148). TAK-279 is an investigational compound that has not been approved for use by any regulatory authority.

About the TAK-279 Phase 2b Study in Psoriasis
The Phase 2b study (NCT04999839) was a randomized, multicenter, double-blind, placebo-controlled multiple-dosed trial designed to evaluate the efficacy, safety and tolerability of TAK-279 in subjects with moderate-to-severe plaque psoriasis. 259 patients were randomly assigned (1:1:1:1:1 ratio) to receive one of four doses of TAK-279 (2mg, 5mg, 15mg, 30mg, all once-daily) or placebo for 12 weeks. The primary endpoint was the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at Week 12.1

About Tyrosine Kinase 2 (TYK2) Inhibitors
Tyrosine kinase 2 (TYK2) is an intracellular enzyme that belongs to the Janus family of protein tyrosine kinases.10 TYK2 is a key part of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, which mediates several key immune cytokine receptors associated with inflammation.11 Increased activation of these inflammatory proteins is associated with several autoimmune diseases, including psoriasis, psoriatic arthritis, systemic lupus erythematosus and inflammatory bowel disease.12 Selective allosteric inhibition of TYK2 may be a promising therapeutic approach to target autoimmune inflammation while potentially avoiding the toxicity associated with JAK inhibitors.13

About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


  1. Armstrong A, Lynde C, Forman S, et al. Efficacy and safety results from the randomized double-blind, placebo-controlled phase 2b trial of TYK2 inhibitor NDI-034858 in moderate-to-severe psoriasis. Presented March 17-21, 2023, New Orleans, Louisiana at the 2023 American Academy of Dermatology Annual Meeting.

  2. Pascoe VL, Enamandram M, Corey KC, et al. Using the Physician Global Assessment in a Clinical Setting to Measure and Track Patient Outcomes. JAMA Dermatol. 2015;151(4):375-381. doi:10.1001/jamadermatol.2014.3513.

  3. National Institute of Arthritis and Musculoskeletal and Skin Diseases [Internet]. Psoriasis. [reviewed 2020 September; cited 2023 February 15]. Available from: https://www.niams.nih.gov/health-topics/psoriasis.

  4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. doi:10.1016/j.jaad.2008.02.039.

  5. American Academy of Dermatology Association [Internet]. Psoriasis: Overview. [cited 2023 February 15]. Available from: https://www.aad.org/public/diseases/psoriasis/what/overview.

  6. National Psoriasis Foundation [Internet]. Psoriasis Statistics. [updated 2022 December 21; cited 2023 February 15]. Available from: https://www.psoriasis.org/psoriasis-statistics/#:~:text=Psoriasis%20by%20the%20Numbers&text=125%20million%20people%20worldwide%20%E2%80%94%202,the%20World%20Psoriasis%20Day%20consortium.

  7. Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341–352. doi:10.1007/s40265-020-01261-8.

  8. Takeda Pharmaceuticals. Data on File.

  9. Gangolli EA, Carreiro S, Leit S, et al. Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in Phase 1 studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858. Presented May 18-21, 2022, Portland, OR at the 2022 Society for Investigative Dermatology Annual Meeting.

  10. Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022;13(1):1–14. doi:10.4331/wjbc.v13.i1.1.

  11. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. doi:10.1038/ni.3691.

  12. Gonciarz M, Pawlak-Buś K, Leszczyński P, et al. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13(13):1135-1150. doi:10.2217/imt-2021-0096.

  13. Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869.



Investor Relations
Christopher O’Reilly
+81 (0) 3-3278-2543

Media Relations
Mark Dole
+1 (857) 352-6349

Japanese Media
Jun Saito
+81 (0) 3-3278-2325



Global Financial Community Optimistic to Overcome Market Challenges and Build Stronger, Tech-Driven, Sustainable Future Economy

 RIYADH, Saudi Arabia - Friday, 17. March 2023 AETOSWire

The second edition of the Financial Sector Conference (FSC 2023) has concluded in Riyadh, with a mood of optimism and energy to overcome market challenges to build a stronger, technology driven and sustainable economy of the future.

Over 3200 participants from 82 countries, and 180 media, assembled in the Saudi capital to discuss the way ahead for the global financial community under the conference theme of “Promising Financial Prospects.”

Representatives from some of the biggest global financial institutions joined Government Finance Ministers met to identify the most effective road map for future growth and prosperity for the sector – enabling greater use of technology; diversification; cross border cooperation and embracing the green economy.

The conference also saw multiple MOUs and agreements signed to support real estate development; FinTech development and digital financing solutions worth billions of dollars and the National Bank of Iraq announced the start of operations in Saudi Arabia.

Concluding the conference, Saudi Central Bank Governor HE Ayman Mohammed Alsayari,

highlighted the Kingdom's efforts to provide an attractive environment for FinTech companies in line with the goals of Vision 2030 goals, and the vital role they play to support the growth of the private sector, to diversify the economy, and to stimulate saving, financing and investment.

Debating the important role of Venture Capital, Courtney Powell, Chief Operating Officer and Managing Partner, 500 Global, said: “Since we made our first investment in the Middle East in 2012, we have seen incredible growth and we have 14 companies today valued at over $100 million. The willingness of the government to support entrepreneurs combined with the opening up of the Kingdom shows it has the potential of becoming a leading global hub for entrepreneurship.”

In discussion about the future of global money flows, HE Giancarlo Giorgetti, Italian Minister of Economy and Finance stated: “In the financial sector, fragmentation induced by geopolitical tension will have strong implications by affecting global and financial stability, the cross-border allocation of capital, international payment systems, and asset prices.”

Financing for the SME sector was a key debating point on the final day of the conference with the enormous growth of the sector both in the Middle East and internationally. Tala Al Jabri, Board Member, Middle East VC Association (MEVCA) identified a major financing gap for the sector. He said: “95% of enterprises in the region are SMEs and the loan profile that goes to them is only 7% – which is the lowest in the world, indicating a massive gap.”

The FinTech sector in Saudi Arabia meanwhile is flourishing as Ziad Alyousef, Deputy Governor for Development and Technology, Saudi Central Bank (SAMA) explained: “In 2018, there were less than 10 companies operating in the FinTech community. Now, there are over 155 companies operating in the space in Saudi Arabia and this has led to increased investments and job creation."




Nawied Jabarkhyl


Sunday, March 19, 2023

WisdomTree Adopts Limited Duration Stockholder Rights Plan

 NEW YORK - Saturday, 18. March 2023

Stockholders to Vote on Rights Plan at 2023 Annual Meeting

(BUSINESS WIRE) -- WisdomTree, Inc. (NYSE: WT) (“WisdomTree” or the “Company”), a global financial innovator, today announced that its Board of Directors (the “Board”) adopted a limited duration stockholder rights plan (the “rights plan”).

The rights plan is intended to protect WisdomTree and its stockholders from efforts by a single stockholder or group of stockholders to obtain control of WisdomTree without paying a control premium. The rights plan is similar to other rights plans adopted by publicly held companies and is intended to promote the fair and equal treatment of all stockholders and to allow stockholders to realize the long-term value of their investment.

The rights plan is substantially similar to the rights plan that the Company adopted last year, and provides several recognized stockholder protections, including the following:

The rights plan will automatically expire on the day after the Company’s 2023 Annual Meeting of Stockholders (“2023 Annual Meeting”), unless approved by stockholders at the 2023 Annual Meeting, in which case it will expire in one year, on March 16, 2024;

The rights will be exercisable only if any person (or any persons acting as a group) acquires 10% (or 20% in the case of passive stockholders) or more of the Company’s outstanding common stock;

The rights plan has an exception for offers made for all shares of the Company that treat all stockholders equally, including a qualifying offer clause that provides stockholders the ability to call a special meeting for purposes of exempting a “qualifying offer;”

The rights plan does not contain any dead-hand, slow-hand, no-hand or similar features that would limit the ability of a future board of directors to redeem the rights; and

The rights plan does not preclude the Board from considering an offer that recognizes the full value of the Company.

Additional Information on Stockholder Rights Plan

Pursuant to the rights plan, WisdomTree declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company’s common stock and 1,000 preferred share purchase rights on each outstanding share of the Company’s Series A Non-Voting Convertible Preferred Stock. The record date for the dividend distribution is March 28, 2023. Initially, the rights will not be exercisable and will trade with the shares of WisdomTree common stock and Series A Preferred Stock. The rights generally will become exercisable if a person or group becomes an “acquiring person” by acquiring 10% (or 20% in the case of passive stockholders) or more of the common stock of WisdomTree (which includes stock subject to a derivative transaction or an acquired derivative security) or if a person or group commences a tender offer that could result in that person or group becoming an “acquiring person.” If a person or group becomes an “acquiring person,” each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of common stock (or, subject to the terms of the rights plan, shares of preferred stock that are equivalent to shares of WisdomTree common stock) having a value of twice the exercise price of the right. If WisdomTree is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the exercise price of the right.

A person or group who beneficially owned 10% or more (or 20% or more in the case of passive stockholders) of WisdomTree’s outstanding common stock prior to the first public announcement by WisdomTree of the adoption of the rights plan will not trigger the rights plan so long as they do not acquire beneficial ownership of any additional shares of common stock at a time when they still beneficially own 10% or more (or 20% or more in the case of passive stockholders) of such common stock, subject to certain exceptions as set forth in the rights plan.

The rights plan will expire on the day after the 2023 Annual Meeting, unless approved by stockholders at the 2023 Annual Meeting, in which case it will expire in one year, on March 16, 2024. The date of the 2023 Annual Meeting has not yet been announced. The rights plan contains a qualifying offer clause that provides stockholders the ability to call a special meeting for purposes of exempting a “qualifying offer.”

Further details about the rights plan will be contained in a Current Report on Form 8-K and in a Registration Statement on Form 8-A that WisdomTree will file with the U.S. Securities and Exchange Commission (“SEC”).


BofA Securities is serving as financial advisor, and Goodwin Procter LLP is serving as legal counsel to WisdomTree. Innisfree M&A is serving as proxy solicitor and H/Advisors Abernathy is serving as strategic communications advisor.

About WisdomTree

WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.

WisdomTree currently has approximately $87.0 billion in assets under management globally.

WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.

Cautionary Statement Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the anticipated benefits and expected consequences of the rights plan that WisdomTree has adopted. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, the effectiveness of the rights plan in providing the Board of Directors with time to make informed decisions that are in the best long-term interests of WisdomTree and its stockholders, and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on February 28, 2023, and in subsequent reports filed with or furnished to the SEC. WisdomTree assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Important Additional Information and Where to Find It

WisdomTree intends to file a proxy statement on Schedule 14A, an accompanying WHITE proxy card and other relevant documents with the SEC in connection with such solicitation of proxies from WisdomTree stockholders for WisdomTree’s 2023 Annual Meeting. WISDOMTREE STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ WISDOMTREE’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), ACCOMPANYING WHITE PROXY CARD, AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of the definitive proxy statement, an accompanying WHITE proxy card, any amendments or supplements to the definitive proxy statement and other documents that WisdomTree files with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the “SEC Filings” section of WisdomTree’s Investor Relations website at http://ir.wisdomtree.com/ or by contacting Jeremy Campbell, Head of Investor Relations, at jeremy.campbell@wisdomtree.com, as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

Certain Information Regarding Participants in the Solicitation

WisdomTree, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from WisdomTree stockholders by WisdomTree in connection with matters to be considered at WisdomTree’s 2023 Annual Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of WisdomTree’s directors and executive officers, in WisdomTree is included in WisdomTree’s definitive proxy statement on Schedule 14A for its 2022 annual meeting of stockholders, filed with the SEC on June 10, 2022, WisdomTree’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 28, 2023, and in WisdomTree’s Current Reports on Form 8-K filed with the SEC from time to time. Changes to the direct or indirect interests of WisdomTree’s directors and executive officers are set forth in SEC filings on Initial Statements of Beneficial Ownership of Securities on Form 3, Statements of Changes in Beneficial Ownership on Form 4 and Annual Statements of Changes in Beneficial Ownership of Securities on Form 5. These documents are available free of charge as described above. Updated information regarding the identities of potential participants and their direct or indirect interests, by security holdings or otherwise, in WisdomTree will be set forth in WisdomTree’s definitive proxy statement for WisdomTree’s 2023 Annual Meeting and other relevant documents to be filed with the SEC, if and when they become available.

Category: Business Update


View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005563/en/




Investor Relations

WisdomTree, Inc.

Jeremy Campbell




Innisfree M&A Incorporated

Scott Winter / Jonathan Salzberger


swinter@innisfreema.com / jsalzberger@innisfreema.com

Media Relations

WisdomTree, Inc.

Jessica Zaloom




H/Advisors Abernathy

Jeremy Jacobs / Dana Gorman

+1 202.774.5600 / +1.212.371.5999

jeremy.jacobs@h-advisors.global / dana.gorman@h-advisors.global